228 related articles for article (PubMed ID: 26696453)
21. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
Gao RL; Xu B; Lansky AJ; Yang YJ; Ma CS; Han YL; Chen SL; Li H; Zhang RY; Fu GS; Yuan ZY; Jiang H; Huo Y; Li W; Zhang YJ; Leon MB;
EuroIntervention; 2013 May; 9(1):75-83. PubMed ID: 23685298
[TBL] [Abstract][Full Text] [Related]
22. A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versus sirolimus-eluting coronary stents in patients with diabetes mellitus (the DiabeDES IV randomized angiography trial).
Maeng M; Baranauskas A; Christiansen EH; Kaltoft A; Holm NR; Krusell LR; Ravkilde J; Tilsted HH; Thayssen P; Jensen LO
Catheter Cardiovasc Interv; 2015 Dec; 86(7):1161-7. PubMed ID: 25640050
[TBL] [Abstract][Full Text] [Related]
23. Comparative Case-Control analysis of a dedicated self-expanding Biolimus A9-eluting Bifurcation stent versus provisional or mandatory side branch intervention strategies in the treatment of coronary bifurcation lesions.
Ohlow MA; Farah A; Richter S; El-Garhy M; von Korn H; Lauer B
Catheter Cardiovasc Interv; 2017 Jul; 90(1):39-47. PubMed ID: 27651317
[TBL] [Abstract][Full Text] [Related]
24. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
[TBL] [Abstract][Full Text] [Related]
25. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.
Kirtane AJ; Leon MB; Ball MW; Bajwa HS; Sketch MH; Coleman PS; Stoler RC; Papadakos S; Cutlip DE; Mauri L; Kandzari DE;
JACC Cardiovasc Interv; 2013 Apr; 6(4):325-33. PubMed ID: 23523453
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcome and chest pain in patients with true versus non-true bifurcation lesions treated with second-generation drug-eluting stents in the TWENTE trial.
van Houwelingen KG; van der Heijden LC; Lam MK; Kok MM; Löwik MM; Louwerenburg JW; Linssen GC; IJzerman MJ; Doggen CJ; von Birgelen C
Heart Vessels; 2016 Nov; 31(11):1731-1739. PubMed ID: 26747438
[TBL] [Abstract][Full Text] [Related]
27. Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES IV trial.
Ahn JM; Park DW; Kim YH; Song H; Cho YR; Kim WJ; Lee JY; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Han S; Lee SY; Lee BK; Cho JH; Yang TH; Lee NH; Yang JY; Park JS; Shin WY; Kim MH; Bae JH; Kim MK; Yoon J; Park SJ
Circ Cardiovasc Interv; 2012 Oct; 5(5):633-40. PubMed ID: 23048051
[TBL] [Abstract][Full Text] [Related]
28. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
Li XT; Sun H; Zhang DP; Xu L; Ni ZH; Xia K; Liu Y; Chi YH; He JF; Li WM; Wang HS; Wang LF; Yang XC
Coron Artery Dis; 2014 Aug; 25(5):405-11. PubMed ID: 24584031
[TBL] [Abstract][Full Text] [Related]
29. 1-Year Results of the REMEDEE Registry: Clinical Outcomes After Deployment of the Abluminal Sirolimus-Coated Bioengineered (Combo) Stent in a Multicenter, Prospective All-Comers Registry.
Woudstra P; Kalkman DN; den Heijer P; Menown IB; Erglis A; Suryapranata H; Arkenbout KE; Iñiguez A; van 't Hof AW; Muller P; Tijssen JG; de Winter RJ
JACC Cardiovasc Interv; 2016 Jun; 9(11):1127-34. PubMed ID: 27209254
[TBL] [Abstract][Full Text] [Related]
30. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.
Almalla M; Schröder J; Pross V; Marx N; Hoffmann R
Catheter Cardiovasc Interv; 2014 May; 83(6):881-7. PubMed ID: 23765557
[TBL] [Abstract][Full Text] [Related]
31. Six-year clinical outcomes of first-generation drug-eluting stents: a propensity-matched analysis.
Tarantini G; Barioli A; Facchin M; Frigo AC; Napodano M; Buja P; D'Amico G; Iliceto S; Isabella G
Coron Artery Dis; 2013 Aug; 24(5):440-8. PubMed ID: 23695366
[TBL] [Abstract][Full Text] [Related]
32. Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents.
Kandzari DE; Leon MB; Meredith I; Fajadet J; Wijns W; Mauri L
JACC Cardiovasc Interv; 2013 May; 6(5):504-12. PubMed ID: 23602459
[TBL] [Abstract][Full Text] [Related]
33. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
34. Rotational atherectomy before paclitaxel-eluting stent implantation in complex calcified coronary lesions: Two-year clinical outcome of the randomized ROTAXUS trial.
de Waha S; Allali A; Büttner HJ; Toelg R; Geist V; Neumann FJ; Khattab AA; Richardt G; Abdel-Wahab M
Catheter Cardiovasc Interv; 2016 Mar; 87(4):691-700. PubMed ID: 26525804
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
Almalla M; Pross V; Marx N; Hoffmann R
Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
[TBL] [Abstract][Full Text] [Related]
36. Randomized study comparing everolimus- and sirolimus-eluting stents in patients with bifurcation lesions treated by provisional side-branch stenting.
Pan M; Medina A; Suárez de Lezo J; Romero M; Segura J; Martín P; Suárez de Lezo J; Hernandez E; Mazuelos F; Ojeda S
Catheter Cardiovasc Interv; 2012 Dec; 80(7):1165-70. PubMed ID: 22511299
[TBL] [Abstract][Full Text] [Related]
37. A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study.
Han YL; Zhang L; Yang LX; Liu HL; Qu P; Li WM; Jiang TM; Li SM; Jing QM; Zhang QY; Xu B; Li Y; Gao RL
EuroIntervention; 2012 Nov; 8(7):815-22. PubMed ID: 23171802
[TBL] [Abstract][Full Text] [Related]
38. Three-year outcome of sirolimus-eluting stent implantation in coronary bifurcation lesions: the provisional side branch stenting approach versus the elective two-stent approach.
Tamura T; Kimura T; Morimoto T; Nakagawa Y; Furukawa Y; Kadota K; Tatami R; Kawai K; Sone T; Miyazaki S; Mitsudo K;
EuroIntervention; 2011 Sep; 7(5):588-96. PubMed ID: 21930463
[TBL] [Abstract][Full Text] [Related]
39. Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: two-year subgroup analysis of the ZEST randomized trial.
Jang SJ; Park DW; Kim WJ; Kim YH; Yun SC; Kang SJ; Lee SW; Lee CW; Park SW; Park SJ
Catheter Cardiovasc Interv; 2013 Jun; 81(7):1106-14. PubMed ID: 22899589
[TBL] [Abstract][Full Text] [Related]
40. The long-term clinical outcome of T-stenting and small protrusion technique for coronary bifurcation lesions.
Naganuma T; Latib A; Basavarajaiah S; Chieffo A; Figini F; Carlino M; Montorfano M; Godino C; Ferrarello S; Hasegawa T; Kawaguchi M; Nakamura S; Colombo A
JACC Cardiovasc Interv; 2013 Jun; 6(6):554-61. PubMed ID: 23683737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
